Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma

Oncogene volume 32, pages 327–340 (2013)Cite this article

Subjects

Abstract

Matrix metalloproteinase-2 (MMP-2) has pivotal role in the degradation of extracellular matrix, and thereby enhances the invasive, proliferative and metastatic potential in cancer. Knockdown of MMP-2 using MMP-2 small interfering RNA (pM) in human glioma xenograft cell lines 4910 and 5310 decreased cell proliferation compared with mock and pSV (scrambled vector) treatments, as determined by 5-bromo-2′-deoxyuridine incorporation, Ki-67 staining and clonogenic survival assay. Cytokine array and western blotting using tumor-conditioned media displayed modulated secretory levels of various cytokines including granulocyte-macrophage colony-stimulating factor, interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-α, angiogenin, vascular endothelial growth factor and PDGF-BB in MMP-2 knockdown cells. Further, cDNA PCR array indicated potential negative regulation of Janus kinase/Stat3 pathway in pM-treated cells. Mechanistically, MMP-2 is involved in complex formation with α5 and β1 integrins and MMP-2 downregulation inhibited α5β1 integrin-mediated Stat3 phosphorylation and nuclear translocation. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays showed inhibited Stat3 DNA-binding activity and recruitment at CyclinD1 and c-Myc promoters in pM-treated cells. In individual experiments, IL-6 or siRNA-insensitive MMP-2 overexpression by pM-FL-A141G counteracted and restored the pM-inhibited Stat3 DNA-binding activity, suggesting IL-6/Stat3 signaling suppression in pM-treated 4910 and 5310 cells. MMP-2/α5β1 binding is enhanced in human recombinant MMP-2 treatments, resulting in elevated Stat3 DNA-binding activity and recruitment on CyclinD1 and c-Myc promoters. Activation of α5β1 signaling by Fibronectin adhesion elevated pM-inhibited Stat3 phosphorylation whereas blocking α5β1 abrogated constitutive Stat3 activation. In vivo experiments with orthotropic tumor model revealed the decreased tumor size in pM treatment compared with mock or pSV treatments. Immunofluorescence studies in tumor sections corroborated our in vitro findings evidencing high expression and co-localization of MMP-2/α5β1, which is decreased upon pM treatment along with significantly reduced IL-6, phospho-Stat3, CyclinD1, c-Myc, Ki-67 and PCNA expression levels. Our data indicate the possible role of MMP-2/α5β1 interaction in the regulation of α5β1-mediated IL-6/Stat3 signaling activation and signifies the therapeutic potential of blocking MMP-2/α5β1 interaction in glioma treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Louis DN . Molecular pathology of malignant gliomas. Annu Rev Pathol 2006; 1: 97–117.

    Article  CAS  PubMed  Google Scholar 

  2. Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Rao JS . Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489–501.

    Article  CAS  PubMed  Google Scholar 

  4. Chang C, Werb Z . The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37–S43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Han X, Nabors LB . Integrins--a relevant target in glioblastoma. Eur J Clin Med Oncol 2010; 2: 59–64.

    Google Scholar 

  6. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683–693.

    Article  CAS  PubMed  Google Scholar 

  7. Chetty C, Lakka SS, Bhoopathi P, Rao JS . MMP-2 alters VEGF expression via aVB3 integrin-mediated PIK/AKT signaling in A549 lung cancer cells. Int J Cancer 2010; 127: 1081–1095.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF . The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem 2004; 279: 26533–26539.

    Article  CAS  PubMed  Google Scholar 

  9. Silletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA . Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 2001; 98: 119–124.

    CAS  PubMed  Google Scholar 

  10. Aoudjit F, Vuori K . Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995–5004.

    Article  CAS  PubMed  Google Scholar 

  11. Courter DL, Lomas L, Scatena M, Giachelli CM . Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kappaB. J Biol Chem 2005; 280: 12145–12151.

    Article  CAS  PubMed  Google Scholar 

  12. Korah R, Boots M, Wieder R . Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res 2004; 64: 4514–4522.

    Article  CAS  PubMed  Google Scholar 

  13. Lee BH, Ruoslahti E . alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J Cell Biochem 2005; 95: 1214–1223.

    Article  CAS  PubMed  Google Scholar 

  14. Matter ML, Ruoslahti E . A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. J Biol Chem 2001; 276: 27757–27763.

    Article  CAS  PubMed  Google Scholar 

  15. Mitra A, Chakrabarti J, Chatterjee A . Binding of alpha5 monoclonal antibody to cell surface alpha5beta1 integrin modulates MMP-2 and MMP-7 activity in B16F10 melanoma cells. J Environ Pathol Toxicol Oncol 2003; 22: 167–178.

    Article  CAS  PubMed  Google Scholar 

  16. Morozevich G, Kozlova N, Cheglakov I, Ushakova N, Berman A . Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle 2009; 8: 2219–2225.

    Article  CAS  PubMed  Google Scholar 

  17. Morozevich GE, Kozlova NI, Cheglakov IB, Ushakova NA, Preobrazhenskaya ME, Berman AE . Implication of alpha5beta1 integrin in invasion of drug-resistant MCF-7/ADR breast carcinoma cells: a role for MMP-2 collagenase. Biochemistry (Mosc) 2008; 73: 791–796.

    Article  CAS  Google Scholar 

  18. Ogier C, Bernard A, Chollet AM, LE DT, Hanessian S, Charton G et al. Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 2006; 54: 272–284.

    Article  PubMed  Google Scholar 

  19. Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4: 11–22.

    Article  CAS  PubMed  Google Scholar 

  20. Hong DS, Angelo LS, Kurzrock R . Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110: 1911–1928.

    Article  CAS  PubMed  Google Scholar 

  21. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003; 103: 642–646.

    Article  CAS  PubMed  Google Scholar 

  22. Song L, Rawal B, Nemeth JA, Haura EB . IL6/JAK1 pathway inhibition downregulates STAT3 and inhibits tumor growth in lung cancer. Mol Cancer Ther 2011; 10: 481–494.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009; 27: 2393–2404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA et al. IL-6 is required for glioma development in a mouse model. Oncogene 2004; 23: 3308–3316.

    Article  CAS  PubMed  Google Scholar 

  25. Bollrath J, Greten FR . IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009; 10: 1314–1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91–102.

    Article  CAS  PubMed  Google Scholar 

  27. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 2001; 98: 7319–7324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 2000; 97: 4227–4232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Levy DE, Inghirami G . STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA 2006; 103: 10151–10152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008; 10: 287–297.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Curran S, Murray GI . Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000; 36: 1621–1630.

    Article  CAS  PubMed  Google Scholar 

  32. Huang C, Yang G, Jiang T, Huang K, Cao J, Qiu Z . Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res 2010; 29: 51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550–3560.

    Article  CAS  PubMed  Google Scholar 

  34. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ . Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002; 21: 8404–8413.

    Article  CAS  PubMed  Google Scholar 

  35. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D et al. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 2011; 101: 393–403.

    Article  CAS  PubMed  Google Scholar 

  36. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka SS . Adenovirus-mediated siRNA against MMP-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 2006; 5: 2289–2299.

    Article  CAS  PubMed  Google Scholar 

  37. Farber K, Synowitz M, Zahn G, Vossmeyer D, Stragies R, Van Rooijen N et al. An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci 2008; 39: 579–585.

    Article  PubMed  Google Scholar 

  38. Maglott A, Bartik P, Cosgun S, Klotz P, Ronde P, Fuhrmann G et al. The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res 2006; 66: 6002–6007.

    Article  CAS  PubMed  Google Scholar 

  39. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R . Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 2008; 615: 47–79.

    Article  CAS  PubMed  Google Scholar 

  40. Martinkova E, Maglott A, Leger DY, Bonnet D, Stiborova M, Takeda K et al. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int J Cancer 2010; 127: 1240–1248.

    Article  CAS  PubMed  Google Scholar 

  41. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002; 22: 5912–5922.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69: 1009–1015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hsu CP, Chen YL, Huang CC, Chou CC, Liu CL, Hung CH et al. Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest 2011; 41: 277–284.

    Article  CAS  PubMed  Google Scholar 

  44. Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ et al. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res 2006; 66: 1526–1535.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006; 5: 2271–2280.

    Article  CAS  PubMed  Google Scholar 

  46. Isaji T, Sato Y, Fukuda T, Gu J . N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1. J Biol Chem 2009; 284: 12207–12216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest New Drugs 2008; 26: 7–12.

    Article  CAS  PubMed  Google Scholar 

  48. Levkau B, Kenagy RD, Karsan A, Weitkamp B, Clowes AW, Ross R et al. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells. Cell Death Differ 2002; 9: 1360–1367.

    Article  CAS  PubMed  Google Scholar 

  49. Mino K, Ozaki M, Nakanishi K, Haga S, Sato M, Kina M et al. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci 2011; 102: 1052–1058.

    Article  CAS  PubMed  Google Scholar 

  50. Kesanakurti D, Chetty C, Bhoopathi P, Lakka SS, Gorantla B, Tsung AJ et al. Suppression of MMP-2 attenuates TNF-alpha induced NF-kappaB activation and leads to JNK mediated cell death in glioma. PLoS One 2011; 6: e19341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Li R, Li G, Deng L, Liu Q, Dai J, Shen J et al. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep 2010; 23: 1553–1559.

    CAS  PubMed  Google Scholar 

  52. Zhang X, Yin P, DI D, Luo G, Zheng L, Wei J et al. IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line. Anticancer Res 2009; 29: 4497–4501.

    CAS  PubMed  Google Scholar 

  53. Ara T, DeClerck YA . Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46: 1223–1231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, Dash R et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 2011; 30: 2345–2355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005; 7: 164–176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Galatioto J, Mascareno E, Siddiqui MA . CLP-1 associates with MyoD and HDAC to restore skeletal muscle cell regeneration. J Cell Sci 2010; 123: 3789–3795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Kesanakurti D, Sareddy GR, Babu PP, Kirti PB . Mustard NPR1, a mammalian IkappaB homologue inhibits NF-kappaB activation in human GBM cell lines. Biochem Biophys Res Commun 2009; 390: 427–433.

    Article  CAS  PubMed  Google Scholar 

  58. Ganji PC, Nalla AK, Gupta R, Mohanam S, Gujrati M, Dinh DH et al. siRNA-mediated downregulation of MMP-9 and uPAR in combination with radiation induces G2/M cell-cycle arrest in medulloblastoma. Mol Cancer Res 2011; 9: 51–66.

    Article  CAS  Google Scholar 

  59. Badiga AV, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein JD et al. MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One 2011; 6: e20614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Shellee Abraham for manuscript preparation and Diana Meister and Sushma Jasti for manuscript review. This research was supported by award NS64535-01A2 (to JSR) from the National Institute of Neurological Disorders and Stroke.

Funding: Contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.

Author information

Authors and Affiliations

  1. Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

    D Kesanakurti, C Chetty & J S Rao

  2. Department of Neurosurgery, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

    D H Dinh & J S Rao

  3. Department of Pathology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA

    M Gujrati

Authors
  1. D Kesanakurti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Chetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D H Dinh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Gujrati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J S Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J S Rao.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kesanakurti, D., Chetty, C., Dinh, D. et al. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma. Oncogene 32, 327–340 (2013). https://doi.org/10.1038/onc.2012.52

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2012.52

Keywords

This article is cited by

Search

Advanced search

Quick links